Skip to ContentSkip to Navigation
founded in 1614  -  top 100 university
Over ons Praktische zaken Waar vindt u ons dr. W.J. Maas

Publicaties

Corrigendum to "Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands" [Eur J Cancer 205 (2024)114125]

Sex-based differences in effectiveness of immune checkpoint inhibitors in the treatment of advanced non-small-cell lung cancer: systematic review and meta-analysis

Changes in global quality of life after treatment with immune checkpoint inhibitors in patients receiving different treatment regimens for advanced stage lung cancer in the Netherlands: a 2015-2021 cohort study

CT-assessed sarcopenia and immune-related adverse events in patients with lung cancer: A competing risk time-to-event analysis

Drive-the-doctor paradigm in acute ischaemic stroke for improving regional stroke care networks: a cost-effectiveness analysis

Optimising regional organisation of endovascular thrombectomy for ischaemic stroke reusing a simulation model

An Innovative Big Temporal Data Analytics Technique over Real-Life Healthcare Datasets: The F-TBDA Approach

PS-20-008 Predictive biomarker testing rates in patients with metastatic non-small cell lung cancer in The Netherlands

Trends in the prescription of immune checkpoint inhibitors for non-small cell lung cancer in the Netherlands from 2016 to 2020, a national cancer registry analysis

Cost-effectiveness of improvement strategies for reperfusion treatments in acute ischemic stroke: a systematic review